Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
NCT04710056 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-03-12
Summary
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Conditions
- Lipodystrophy
- Generalized Lipodystrophy (GLD)
- Monogenic Obesity (MOB)
Interventions
- DRUG
-
REGN4461
To be provided by Regeneron
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
NCT07171723 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Short-term Effects of Leptin in People With Lipodystrophy
NCT01778556 ·Status: COMPLETED ·Phase: PHASE2
-
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI
NCT01562678 ·Status: COMPLETED ·Phase: PHASE4
-
Leptin to Treat Lipodystrophy
NCT00025883 ·Status: COMPLETED ·Phase: PHASE2
-
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
NCT02920190 ·Status: WITHDRAWN ·Phase: PHASE4
-
Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury
NCT02001363 ·Status: UNKNOWN ·Phase: NA
-
Cardiovascular Effects of GLP-1 Receptor Activation
NCT03101930 ·Status: COMPLETED ·Phase: PHASE4
-
In Vivo Leptin Signaling in Humans After Acute Leptin Administration
NCT01275053 ·Status: COMPLETED ·Phase: PHASE1
-
Liraglutide in Type 1 Diabetes
NCT01612468 ·Status: COMPLETED ·Phase: PHASE4
-
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213 ·Status: COMPLETED
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4
-
RYGB and the Gastric Adipose Axis
NCT01474785 ·Status: COMPLETED ·Phase: PHASE1
-
Liraglutide In Overweight Patients With Type 1 Diabetes
NCT01753362 ·Status: COMPLETED ·Phase: PHASE3
-
Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT00027456 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
NCT07073053 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
NCT04657939 ·Status: COMPLETED ·Phase: PHASE4
-
Liraglutide in Type 1 Diabetes
NCT01722240 ·Status: COMPLETED ·Phase: PHASE3
-
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
NCT02198209 ·Status: WITHDRAWN ·Phase: PHASE4
-
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
NCT04387201 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure
NCT00264199 ·Status: COMPLETED ·Phase: NA
-
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664 ·Status: COMPLETED ·Phase: PHASE3
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA
-
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609 ·Status: COMPLETED ·Phase: NA
-
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Expanded Access Metreleptin Study
NCT02404896 ·Status: AVAILABLE